SIGLEC14 and cancer: Potential plasma biomarker candidates for sequential validation experiments were first selected among differentially expressed proteins that met one or more of the following criteria: (1) identified as differentially expressed proteins (PLXND1, SND1, SIGLEC14, and PRMT1) with FDR-adjusted p value <0.05 and (2) previously found to be differentially expressed in frozen tissues between the good and poor prognosis groups of patients with HGSOC (10), considering that increased levels of cancer tissue-specific proteins can be released into the blood (30).